Bayer’s Moment of Truth: Legal Victory, New Subsidiary, and the 53.86 Euro Milestone
Published on 07/03/2026 at 11:12 | Redaktion boerse-global.de
The seeds of Bayer’s turnaround were planted long before the gavel fell. On 25 June 2026, the US Supreme Court ruled 7-2 in the case Monsanto v. Durnell, handing the Dax-listed giant a decisive win. Federal law now preempts state-level claims over missing cancer warnings on glyphosate packaging, wiping out the legal foundation for tens of thousands of pending lawsuits. For a company that has been mired in litigation since its $63 billion Monsanto acquisition, the verdict amounts to a regulatory earthquake – and a green light for structural change.
Just days later, on 1 July, Bayer unveiled the new US subsidiary Ruveon LLC, headquartered in St. Louis. The entity takes full control of pricing, sales, and production for the American glyphosate market, operating with far greater autonomy while remaining under the Leverkusen umbrella. The move is widely seen as paving the way for a potential partial initial public offering of the agricultural division. At the same time, Bayer has filed a petition with US authorities seeking antidumping duties on Chinese glyphosate imports, signalling an aggressive posture toward Asian competition.
Investors wasted little time pricing in the double catalyst. Over the past 30 days, the stock has surged 53.28%, and on the day following the Supreme Court announcement it closed at 53.08 euros. Earlier in the session, the share price touched a fresh 52-week high of 53.86 euros before easing to 52.88 euros amid profit-taking. Since the start of 2024, Bayer’s equity has gained roughly 40%.
Should investors sell immediately? Or is it worth buying Bayer?
Yet the rapid ascent has pushed technical indicators into dangerous territory. The relative strength index stands at 84.1, deep in overbought territory, a level that historically precedes a period of consolidation or a pullback. The shares currently trade nearly 38% above their 50-day moving average, underscoring the extent of the rally. For the near term, the key battleground is the 50-euro mark; if that level holds, the stock may build a base for further gains.
Away from the courtroom and the trading screen, CEO Bill Anderson is driving a parallel transformation. Since early 2024, Bayer has eliminated more than 12,000 positions as part of a sweeping cost-cutting effort designed to flatten hierarchies and accelerate decision-making. The pharmaceutical pipeline is also showing signs of life: Nubeqa, a cancer drug, posted sales growth of over 50% in the second quarter, while the newly approved menopause treatment Lynkuet is generating strong expectations for the post-Xarelto patent era.
Market watchers are recalibrating their outlook in light of the legal relief. Deutsche Bank upgraded the stock to “Buy” on 2 July, arguing that provisions for residual litigation are now sufficient to cover remaining exposure. With the glyphosate risk finally becoming calculable, analysts are refocusing on Bayer’s underlying operational performance.
The combination of a definitive legal win and a strategic restructuring creates a platform for a valuation re-rating – if the stock can defend its recent gains. As the management prepares to release detailed terms of the Ruveon carve-out in the coming months, the market will be watching for signs that the rally has room to run beyond the 53.86 euro peak.
Ad
Bayer Stock: New Analysis - 3 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
